Epigenetic markers could point to type 1 diabetes risk; Gene discovery indicates osteoporosis risk;

> New biomarker tests could provide an alternative to biopsies to track disease in patients with lupus. Release

> Fecal biomarkers of inflammation could beat a path to new diagnostics and ways of caring for patients with inflammatory bowel disease, according to experts from the Sydney Children's Hospital in Australia. Abstract

> Scientists discover that epigenetic clues could become important markers for type 1 diabetes risk and point to new non-genetic underpinnings of the metabolic disorder. Article

> A new gene discovery could provide a marker determining a patient's risk for osteoporosis. Release

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.